Table 1.
Patient demographics in the 3 induction groups
| Induction type | Thymoglobulin (140) | Alemtuzumab (134) | Basiliximab (134) | P |
|---|---|---|---|---|
| Donor age mean (95% CI for mean) | 49.7 (47.1–52.35) | 48.4 (45.3–51.5) | 48.3 (45–51.6) | 0.76 |
| Donor sex M/F (%) | 99/41 (70.7/29.3) | 79/49 (59/36.6) 6 missing (4.5%) |
72/53 (51.4/37/9) 15 missing (10.7%) |
0.5 |
| Recipient age mean (95% CI for mean) | 53.6 (51.6–55.6) | 52.4 (50.3–54.4) | 51.9 (50–53.8) | 0.46 |
| Recipient sex M/F (%) | 101/39 (72.1/27.9) | 91/43 (67.9/32.1) | 99/41 (70.7/29.3) | 0.7 |
| CIT in h mean (95% CI for mean) | 13.1 (12.37–13.9) | 13.3 (12.37–14.28) | 12.4 (11.53–13.39) | 0.36 |
| DR mismatch 0/1 or 2 (%) | 25/83/32 (17.9/59.3/22.9) | 38/79/17 (28.4/59/12.7) | 44/78/18 (31.4/55.7/12.9) | <0.001 |
| Total HLA mismatch 0/1–4/5–6 (%) | 1/105/34 (0.7/75/24.3) | 3/112/19 (2.2/83.6/14.2) | 3/114/20 (2.14/81.43/14.3) | <0.001 |
| Diabetes as cause of ESRF (%) | 14 (10%) | 15 (11.1) | 14 (10) | 0.84 |
CIT, cold ischemic time; DR, DR isotyope; ESRF, end-stage renal failure; F, female; HLA, human leukocyte antigen; M, male.
There were more patients with 1 or 2 HLA-DR mismatches and 1 to 4 and 5 to 6 total HLA mismatches among the patients who received thymoglobulin compared with those who received either alemtuzumab or basiliximab.